After discontinuing lurasidone (Latuda) 40 mg two weeks ago and using lorazepam (Ativan) 1 mg nightly for withdrawal symptoms, when is it safe to stop the lorazepam?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

When to Stop Ativan After Latuda Discontinuation

You should begin tapering the Ativan (lorazepam) now, as two weeks is sufficient time to have managed acute lurasidone withdrawal symptoms, and continuing benzodiazepines beyond short-term use risks developing dependence with its own withdrawal syndrome.

Rationale for Tapering Now

Lurasidone (Latuda) is not associated with a physical withdrawal syndrome requiring benzodiazepine coverage 1. The symptoms you experienced after stopping Latuda were likely related to the underlying condition returning or discontinuation effects, not a withdrawal syndrome requiring extended benzodiazepine treatment. Benzodiazepines like lorazepam should only be used short-term (typically days to weeks, not months) to avoid creating a separate dependence problem 2, 3.

The critical concern now is that you've been taking lorazepam nightly for two weeks. While this is relatively short-term use, continuing beyond this point significantly increases your risk of benzodiazepine dependence, which carries serious risks including:

  • Rebound anxiety and insomnia upon discontinuation 4, 5
  • Potential for seizures with abrupt cessation 2, 3, 6
  • Cognitive impairment with continued use 7
  • Development of tolerance requiring higher doses 8

Recommended Tapering Schedule

For your situation (1 mg nightly for 2 weeks), use a gradual taper over 1-2 weeks 2, 3:

Week 1:

  • Days 1-3: 0.75 mg at night (25% reduction)
  • Days 4-7: 0.5 mg at night (50% reduction from original)

Week 2:

  • Days 8-10: 0.25 mg at night
  • Days 11-14: 0.25 mg every other night
  • Day 15: Discontinue

This represents a 25% dose reduction every 3-4 days, which aligns with the commonly used and safe tapering schedule of 25% reduction every 1-2 weeks 2, 3. Given your relatively short duration of use (2 weeks), a faster taper is appropriate compared to long-term users.

Important Caveats

Do not stop abruptly. Even after just 2 weeks of use, abrupt discontinuation can cause rebound anxiety, insomnia, and in rare cases, seizures 2, 3, 6. Gradual tapering minimizes these risks 4.

Monitor for withdrawal symptoms during the taper:

  • Increased anxiety or panic
  • Insomnia or sleep disturbance
  • Irritability
  • Tremor or sweating
  • Perceptual changes
  • Headache or muscle tension 5

If significant withdrawal symptoms emerge, slow the taper rate (reduce by smaller increments over longer intervals) rather than stopping the taper entirely 4.

Alternative Approaches to Anxiety/Sleep

Rather than continuing benzodiazepines, consider:

  • Cognitive-behavioral therapy (CBT) for anxiety or insomnia, which increases successful benzodiazepine discontinuation rates 2, 3
  • Non-benzodiazepine anxiolytics if anxiety persists (SSRIs, SNRIs, buspirone) 2
  • Sleep hygiene measures for insomnia rather than medications 4

Critical Warning

The longer you continue lorazepam, the harder it becomes to stop. Patients on therapeutic doses for months to years require much slower tapers (weeks to months) and face higher risks of protracted withdrawal 2, 3, 7. At two weeks, you're at an ideal window to discontinue before significant dependence develops.

Contact your prescriber before starting this taper to ensure they agree with the plan and can monitor your progress. If you experience severe anxiety, insomnia, or other concerning symptoms during the taper, contact them immediately rather than stopping the taper or resuming the full dose.

References

Guideline

prevention and control of seasonal influenza with vaccines.

MMWR Recommendations and Reports, 2016

Guideline

clinical guideline for the evaluation and management of chronic insomnia in adults.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2008

Research

The benzodiazepine withdrawal syndrome.

Addiction (Abingdon, England), 1994

Research

Benzodiazepine withdrawal seizures and management.

The Journal of the Oklahoma State Medical Association, 2011

Research

Tolerance and withdrawal after chronic lorazepam treatment in rats.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1993

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.